

C1  
B2  
5. (Amended) A vaccine which is protective against *Mycoplasma bovis* clinical disease in a bovine species comprising at least one inactivated or attenuated *Mycoplasma bovis* biotype and a pharmaceutically acceptable excipient, wherein at least one of the inactivated or attenuated *Mycoplasma bovis* biotypes is selected from the group consisting of biotype A, biotype B and biotype C.

Please add the following new claims:

sub  
C1  
22. (New) The vaccine of claim 21, comprising at least two inactivated *Mycoplasma bovis* biotypes and a pharmaceutically acceptable excipient, wherein the vaccine is protective against *Mycoplasma bovis* mastitis in a bovine species following systemic administration.

23. (New) The vaccine of claim 21, wherein the vaccine does not include saponin.

sub  
C1  
B3  
24. (New) The vaccine of claim 21, wherein the vaccine includes at least one inactivated *Mycoplasma bovis* biotype selected from the group consisting of biotype A, biotype B and biotype C.

25. (New) The vaccine of claim 1, comprising at least two inactivated or attenuated *Mycoplasma bovis* biotypes and a pharmaceutically acceptable excipient.

26. (New) The vaccine of claim 25, wherein at least two of the at least two inactivated or attenuated *Mycoplasma bovis* biotypes can be distinguished from one another by PCR fingerprinting.